Key Highlights
- Revenue of USD 22.84 million missed the USD 24.94 million estimate, while loss per share was USD 0.78.
- Net KOMZIFTI product Revenue was USD 13.9 million, up 53% sequentially, while collaboration revenue fell to USD 8.9 million.
- Net loss narrowed to USD 70.2 million from USD 74.1 million, and nine-month net loss was USD 211.9 million.
- Cash, cash equivalents and short-term investments totaled USD 492.1 million at September 30, 2026, down from December.
Kura Oncology (NASDAQ:KURA), a clinical-stage and commercial biopharmaceutical company, reported third quarter 2026 revenue of USD 22.84 million, below the USD 24.94 million estimate. Loss per share of USD 0.78 was narrower than the estimated USD 0.82 loss and compared with USD 0.85 a year earlier. Net loss was USD 70.2 million against USD 74.1 million.
Revenue combined USD 13.9 million of net product revenue from KOMZIFTI sales in the United States, following FDA approval in November 2025, and USD 8.9 million of collaboration revenue under the Kyowa license agreement. Collaboration revenue was USD 20.8 million in the prior-year quarter, when the company had no product revenue.
Launch Metrics and Nine-Month Results
Management said net product revenue rose 53% sequentially and that new patient starts increased about 30% to roughly 150. It cited more than 2,400 total prescriptions, up 65%, and 170 accounts that have prescribed the drug, up 40% from the prior quarter. Field teams reached 97% of the highest priority AML accounts, and management said coverage extends to nearly all covered lives.
For the nine months, product revenue was USD 28.8 million and collaboration revenue was USD 33.2 million against USD 50.1 million. Net loss was USD 211.9 million against USD 197.7 million, and loss per share was USD 2.38 against USD 2.26.
Cash, Caspian and Clinical Programs
Cash, cash equivalents and short-term investments totaled USD 492.1 million at September 30, 2026, made up of USD 57.9 million in cash and USD 434.2 million in short-term investments. On September 8, Caspian, a company in which Kura Oncology holds an interest, completed a USD 50.0 million Series A preferred financing, and Kura Oncology invested USD 4.3 million. The filing reports its holdings were about 49.2% of Caspian's outstanding Capital Stock afterward, and a gain on deconsolidation of about USD 30.6 million was offset by a loss on the Equity method Investment of about the same amount.
Management highlighted four oral presentations at the ASH meeting, including first clinical data for ziftomenib combined with FLT3 inhibitors in newly diagnosed and relapsed or refractory AML, from the KOMET-007 and KOMET-008 trials. It said it continues to anticipate first topline results from the intensive chemotherapy trial in 2028.
Regulatory Basis and Items to Follow
The filing states that FDA approval was based on the KOMET-001 trial of 112 patients with relapsed or refractory NPM1-mutated AML, in which the complete remission plus partial hematologic Recovery Rate was 21.4%. Its Legal Proceedings item states the company is not currently a party to any material legal proceedings. The items to follow are prescription growth, collaboration revenue timing, spending and the ASH data.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...